Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-α agents in patients with rheumatoid arthritis: a retrospective chart review analysis
- 43 Downloads
Data are scarce regarding the association of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) with treatment response and persistence of anti-TNF-α agents in patients with rheumatoid arthritis (RA). Thus, we investigated whether baseline NLR and PLR could predict 12-week treatment response and long-term persistence of anti-TNF-α agents in RA patients. This is a retrospective chart review analysis of 82 women with RA who started anti-TNF-α agents as the first-line biologic therapy and 328 healthy age-matched women. RA patients were divided into high and low baseline NLR or PLR subgroups using the median split. European League against Rheumatism (EULAR) treatment response was evaluated at 12 weeks. RA patients had significantly higher NLR and PLR than controls. High baseline NLR and PLR groups showed higher 12-week EULAR non-response rate than low NLR (30% vs 7.1%, p = 0.01) and PLR groups (27.5% vs 9.5%, p = 0.047), respectively. After adjusting for confounding factors, high baseline NLR (OR 5.57, p = 0.014) and PLR (OR 4.24, p = 0.04) were significantly associated with a higher risk of EULAR non-response at 12 weeks. During the study period, 47 (57.3%) RA patients (lack of efficacy: n = 31; adverse events: n = 16) discontinued anti-TNF-α agents. High baseline NLR was associated with an increased risk of anti-TNF-α agent withdrawal due to lack of efficacy (HR 2.12, p = 0.045). Our data suggest that baseline NLR and PLR are useful markers for predicting the treatment outcome of anti-TNF-α agents in RA patients.
KeywordsRheumatoid arthritis Tumor necrosis factor-alpha Blood cells Treatment outcome Biomarkers
We specially thank the late Professor Sung-Il Kim who devoted himself to education, research, and patient care in Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine (1963–2011).
HNL: study design, data collection and analysis and writing manuscript, YKK: data interpretation, GTK: data interpretation and revision of manuscript, MWS: data interpretation and revision of manuscript, EA: data interpretation, DHS: data interpretation and revision of manuscript, SGL: study design, data analysis and interpretation, writing manuscript and coordination of entire study.
This work was supported by a clinical research Grant from Pusan National University Hospital in 2019.
Compliance with ethical standards
Conflict of interest
The authors have declared no conflicts of interest.
This study protocol was approved by the by the Research and Ethical Review Board of the Pusan National University Hospital, which waived written informed consent due to retrospective study design (IRB no. 1809-010-071).
- 1.Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3–15. https://doi.org/10.1136/annrheumdis-2015-207524 CrossRefGoogle Scholar
- 3.Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poor G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977. https://doi.org/10.1136/annrheumdis-2016-210715 CrossRefGoogle Scholar
- 4.Simsek I (2012) Predictors of response to TNF inhibitors in rheumatoid arthritis—do we have new tools for personalized medicine?. Bull NYU Hosp Jt Dis 70 (3):187–190Google Scholar
- 5.Simsek I (2010) TNF inhibitors—new and old agents for rheumatoid arthritis. Bull NYU Hosp Jt Dis 68(3):204–210Google Scholar
- 10.Sun Y, Xia L, Wang H, Chen Z, Wu Y, Chen B, Shi H, Feng Y, Yin S (2018) Is nucleate cell count and neutrophil to lymphocyte ratio related to patients with audiographically distinct sudden sensorineural hearing loss? Medicine 97(20):e10586. https://doi.org/10.1097/MD.0000000000010586 CrossRefGoogle Scholar
- 11.Zhang L, Wang Y, Han J, Shen H, Zhao M, Cai S (2018) Neutrophil-lymphocyte ratio, gamma-glutamyl transpeptidase, lipase, high-density lipoprotein as a panel of factors to predict acute pancreatitis in pregnancy. Medicine 97(26):e11189. https://doi.org/10.1097/md.0000000000011189 CrossRefGoogle Scholar
- 13.Nishida Y, Hosomi S, Yamagami H, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Fujiwara Y (2017) Neutrophil-to-lymphocyte ratio for predicting loss of response to infliximab in ulcerative colitis. PloS One 12(1):e0169845. https://doi.org/10.1371/journal.pone.0169845 CrossRefGoogle Scholar
- 14.Coskun BN, Oksuz MF, Ermurat S, Tufan AN, Orucoglu N, Dogan A, Dalkilic E, Pehlivan Y (2014) Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti-tumor necrosis factor (TNF) drugs for ankylosing spondylitis. Eur J Rheumatol 1(3):101–105. https://doi.org/10.5152/eurjrheumatol.2014.034 CrossRefGoogle Scholar
- 17.Uslu AU, Kucuk A, Sahin A, Ugan Y, Yilmaz R, Gungor T, Bagcaci S, Kucuksen S (2015) Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil–lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis 18(7):731–735. https://doi.org/10.1111/1756-185X.12582 CrossRefGoogle Scholar
- 20.Chandrashekara S, Rajendran A, Bai Jaganath A, Krishnamurthy R (2015) Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis. Reumatismo 67(3):109–115. https://doi.org/10.4081/reumatismo.2015.838 CrossRefGoogle Scholar
- 21.Maden M, Pamuk GE, Pamuk ON (2017) Development of atherosclerotic cardiovascular mortality in gouty arthritis and rheumatoid arthritis patients: are they associated with mean platelet volume and neutrophil-lymphocyte ratio? A comparative study. Arch Rheumatol 32(1):39–45. https://doi.org/10.5606/ArchRheumatol.2017.6033 CrossRefGoogle Scholar
- 23.Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48CrossRefGoogle Scholar
- 24.van Riel PL (2014) The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol 32(5 Suppl 85):S–S65Google Scholar
- 25.van Gestel AM, Prevoo ML, van ‘t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34–40CrossRefGoogle Scholar
- 28.Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR, Harrison DJ, Cannon GW (2017) persistence with conventional triple therapy versus a tumor necrosis factor inhibitor and methotrexate in US veterans with rheumatoid arthritis. Arthritis Care Res 69(3):313–322. https://doi.org/10.1002/acr.22944 CrossRefGoogle Scholar
- 30.Lee MY, Shin JY, Park SY, Kim D, Cha HS, Lee EK (2018) Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: an analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum 47(4):485–491. https://doi.org/10.1016/j.semarthrit.2017.08.007 CrossRefGoogle Scholar
- 31.Jones G, Hall S, Bird P, Littlejohn G, Tymms K, Youssef P, Chung E, Barrett R, Button P (2018) A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis 21(8):1581–1590. https://doi.org/10.1111/1756-185X.13243 CrossRefGoogle Scholar
- 32.Yang Z, Zhang Z, Lin F, Ren Y, Liu D, Zhong R, Liang Y (2017) Comparisons of neutrophil-, monocyte-, eosinophil-, and basophil- lymphocyte ratios among various systemic autoimmune rheumatic diseases. APMIS Acta Pathologica Microbiologica Et Immunologica Scandinavica 125(10):863–871. https://doi.org/10.1111/apm.12722 CrossRefGoogle Scholar
- 41.Gomez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C, Montoro M, Descalzo MA, Carmona L (2012) Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 71(3):382–385. https://doi.org/10.1136/annrheumdis-2011-200302 CrossRefGoogle Scholar